Ceregene Inc., of San Diego, said the regents of the University of California received U.S. Patent No. 6,683,058 relating to gene therapy methods that could be applied to the treatment of neurodegenerative conditions, including Alzheimer's and Parkinson's disease. Ceregene has an exclusive worldwide license to the patent.

Epimmune Inc., of San Diego, was granted U.S. Patent No. 6,689,363, directed to compositions and methods of using antigen fragments, or epitopes, to induce T-cell immune responses for the prevention or treatment of hepatitis B virus infection.

GB Therapeutics Ltd., of Mississauga, Ontario, was issued U.S. Patent No. 6,677,374, which is related to its nitric oxide mimetic compounds as they relate to effecting neurodegeneration, mitigating neurodegeneration and/or cognition enhancement.

GlycoGenesys Inc., of Boston, was awarded U.S. Patent No. 6,680,306 titled "Method for Enhancing the Effectiveness of Cancer Therapies," covering the use of GCS-100 and other carbohydrates that bind to galectins prior to or in combination with chemotherapy or surgery for the treatment of cancer.

Immtech International Inc., of Vernon Hills, Ill., received U.S. Patent No. 9,703,804 titled "Methods and Formulations For the Treatment of Infectious Bursal Disease in Avian Subjects," protecting a new class of dicationic compounds to be used to treat infectious bursal disease-related infections in chickens and other poultry, including methods to improve the vaccination of avian livestock.